Shares in MGC Pharmaceuticals have risen more than 40 per cent after the WA company revealed first orders for its plant-derived medicinal products in the US.
Admedus has appointed Michael Oswell to the newly created role of vice president, development. Based in the US, Mr Oswell has extensive experience in the medical technology industry.
ASX-listed MGC Pharmaceuticals announced today that is has been awarded a contract to build a medical cannabis production facility in Malta, with a $5 million capital raising set to help fund the project.
Roby Zomer, founder of MGC Pharmaceuticals, has been appointed chief executive officer. Mr Zomer was its executive director and chief technical officer prior to this appointment.